No influence on disease progression of non-HLA susceptibility genes in MS

Journal of Neuroimmunology

Volumn 237, Issue 1-2, 2011, Pages 98-100

  Lundström, Wangko ^a   Greiner, Eva ^a   Lundmark, Frida ^a   Westerlind, Helga ^a   Smestad, Cathrine ^b   Lorentzen, Aslaug R ^b,c   Kockum, Ingrid ^a   Link, Jenny ^a   Brynedal, Boel ^a   Celius, Elisabeth G ^b   Harbo, Hanne F ^b,d   Masterman, Thomas ^a   Hillert, Jan ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

EDSS; Genotype; MSSS; Multiple sclerosis; Severity; SNPs

Indexed keywords

ADULT; ARTICLE; CD226 GENE; CLEC16A GENE; DISEASE COURSE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HLA SYSTEM; HUMAN; IL2RA GENE; IL7R GENE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SCANDINAVIA; SH2B3 GENE;

EID: 80051469284     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2011.05.003     Document Type: Article

References (17)

1. Brynedal B., Wojcik J., Esposito F., Debailleul V., Yaouanq J., Martinelli-Boneschi F., Edan G., Comi G., Hillert J., Abderrahim H. MGAT5 alters the severity of multiple sclerosis. J. Neuroimmunol. 2010, 220:120-124.
2. Bush W.S., Sawcer S.J., de Jager P.L., Oksenberg J.R., McCauley J.L., Pericak-Vance M.A., Haines J.L. Evidence for polygenic susceptibility to multiple sclerosis-the shape of things to come. Am. J. Hum. Genet. 2010, 86:621-625.
3. DeLuca G.C., Ramagopalan S.V., Herrera B.M., Dyment D.A., Lincoln M.R., Montpetit A., Pugliatti M., Barnardo M.C., Risch N.J., Sadovnick A.D., Chao M., Sotgiu S., Hudson T.J., Ebers G.C. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:20896-20901.
4. Dyment D.A., Ebers G.C., Sadovnick A.D. Genetics of multiple sclerosis. Lancet Neurol. 2004, 3:104-110.
5. Hafler D.A., Compston A., Sawcer S., Lander E.S., Daly M.J., De Jager P.L., de Bakker P.I., Gabriel S.B., Mirel D.B., Ivinson A.J., Pericak-Vance M.A., Gregory S.G., Rioux J.D., McCauley J.L., Haines J.L., Barcellos L.F., Cree B., Oksenberg J.R., Hauser S.L. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 2007, 357:851-862.
6. Hawkes C.H., Macgregor A.J. Twin studies and the heritability of MS: a conclusion. Mult. Scler. 2009, 15:661-667.
7. Hensiek A.E., Seaman S.R., Barcellos L.F., Oturai A., Eraksoi M., Cocco E., Vecsei L., Stewart G., Dubois B., Bellman-Strobl J., Leone M., Andersen O., Bencsik K., Booth D., Celius E.G., Harbo H.F., Hauser S.L., Heard R., Hillert J., Myhr K.M., Marrosu M.G., Oksenberg J.R., Rajda C., Sawcer S.J., Sorensen P.S., Zipp F., Compston D.A. Familial effects on the clinical course of multiple sclerosis. Neurology 2007, 68:376-383.
8. Imrell K., Greiner E., Hillert J., Masterman T. HLA-DRB115 and cerebrospinal-fluid-specific oligoclonal immunoglobulin G bands lower age at attainment of important disease milestones in multiple sclerosis. J. Neuroimmunol. 2009, 210:128-130.
9. Jensen C.J., Stankovich J., Van der Walt A., Bahlo M., Taylor B.V., van der Mei I.A., Foote S.J., Kilpatrick T.J., Johnson L.J., Wilkins E., Field J., Danoy P., Brown M.A., Rubio J.P., Butzkueven H. Multiple sclerosis susceptibility-associated SNPs do not influence disease severity measures in a cohort of Australian MS patients. PLoS One 2010, 5:e10003.
10. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
11. Lundmark F., Duvefelt K., Iacobaeus E., Kockum I., Wallstrom E., Khademi M., Oturai A., Ryder L.P., Saarela J., Harbo H.F., Celius E.G., Salter H., Olsson T., Hillert J. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat. Genet. 2007, 39:1108-1113.
12. Miller D.H., Leary S.M. Primary-progressive multiple sclerosis. Lancet Neurol. 2007, 6:903-912.
13. Purcell S.M., Wray N.R., Stone J.L., Visscher P.M., O'Donovan M.C., Sullivan P.F., Sklar P. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460:748-752.
14. Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol. Sci. 2001, 22:117-139.
15. Roxburgh R.H., Seaman S.R., Masterman T., Hensiek A.E., Sawcer S.J., Vukusic S., Achiti I., Confavreux C., Coustans M., le Page E., Edan G., McDonnell G.V., Hawkins S., Trojano M., Liguori M., Cocco E., Marrosu M.G., Tesser F., Leone M.A., Weber A., Zipp F., Miterski B., Epplen J.T., Oturai A., Sorensen P.S., Celius E.G., Lara N.T., Montalban X., Villoslada P., Silva A.M., Marta M., Leite I., Dubois B., Rubio J., Butzkueven H., Kilpatrick T., Mycko M.P., Selmaj K.W., Rio M.E., Sa M., Salemi G., Savettieri G., Hillert J., Compston D.A. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005, 64:1144-1151.
16. Smestad C., Brynedal B., Jonasdottir G., Lorentzen A.R., Masterman T., Akesson E., Spurkland A., Lie B.A., Palmgren J., Celius E.G., Hillert J., Harbo H.F. The impact of HLA-A and -DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients. Eur. J. Neurol. 2007, 14:835-840.
17. Wray N.R., Goddard M.E., Visscher P.M. Prediction of individual genetic risk to disease from genome-wide association studies. Genome Res. 2007, 17:1520-1528.